Clin2
NCT06324461Possibly a fitRecruiting

GLP-1 drug to protect heart after non-emergency surgery

Myocardial Injury

Treatments studied

Part of Heart & circulation clinical trials.

This study tests whether a GLP-1 receptor agonist (a medication used for diabetes and weight loss) can reduce heart damage during or after planned non-cardiac surgery. It may help patients with heart risk undergoing intermediate to high-risk procedures.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
372 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You are scheduled for a planned non-cardiac surgery that carries moderate to high risk
  • You will stay in the hospital for at least one night after surgery
  • You have not had low blood sugar symptoms in the past month
  • You have no history of pancreatitis, certain thyroid cancers, or other specified serious conditions

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07295223Recruiting· Phase 3
GLP-1 and SGLT2 drugs for heart attack recovery

This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.

León, Guanajuato
NCT06361238Recruiting· Phase 3
Liraglutide to prevent confusion after heart surgery in seniors with diabetes

This trial is testing if liraglutide, a diabetes medication, can prevent delirium (sudden confusion) in older adults with type 2 diabetes who are having planned heart surgery. If you qualify, you may help find a new way to protect brain function after surgery.

Nanjing, Jiangsu
NCT07073053Not yet recruiting· Phase 4
GLP-1 agonists for heart disease in diabetes

This study is testing whether a class of diabetes medicines called GLP-1 receptor agonists can help people with type 2 diabetes and coronary artery disease. If you have recently had a heart artery-opening procedure and are already taking another diabetes medicine called an SGLT2 inhibitor, this trial may be a good fit for you.

Taipei
NCT06461377Recruiting· Phase 4
GLP-1RA for heart nerve damage in type 2 diabetes

This trial tests whether a type of diabetes medicine called GLP-1RA can help prevent or improve nerve damage in the heart caused by diabetes. It is for people with type 2 diabetes who are overweight or obese.

Nanjing, Jiangsu
NCT07633639Recruiting
GLP-1 Medicine After Weight-Loss Surgery in Chinese Patients

This trial tests whether adding a GLP-1 medication (a type of diabetes and weight-loss drug) after weight-loss surgery helps patients with obesity and related health conditions like diabetes. Researchers want to see if combining surgery with this medicine works better than surgery alone.

Beijing
NCT07601867Recruiting
Dapagliflozin to improve heart function after bypass surgery

This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.

Pyatigorsk, Stavropol Kray

Hear when a new Myocardial Injury trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.